Taigen Biopharmaceuticals Holdings Ltd operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Taigen Biopharmaceuticals Holdings Ltd with three other
companies in this sector in Taiwan:
Sunmax Biotechnology Co Limited
sales of 155.53 million Taiwanese Dollars [US$5.33 million]
of which 76%
was China Mainland),
Tpg Biologics Inc
(48.22 million Taiwanese Dollars [US$1.65 million]
Obi Pharma Inc
(92.42 million Taiwanese Dollars [US$3.16 million]
of which 100%
was Division 1).
Taigen Biopharmaceuticals Holdings Ltd reported sales of 146.02 million Taiwanese Dollars (US$5.00 million)
December of 2016.
increase of 87.2%
versus 2015, when the company's sales were 78.00 million Taiwanese Dollars.
Sales of Medical Development saw an increase
156.9% in 2016, from
51.18 million Taiwanese Dollars to 131.49 million Taiwanese Dollars.
Not all segments of Taigen Biopharmaceuticals Holdings Ltd experienced an increase in sales in 2016:
sales of Medical Consultance fell 45.8% to 14.53 million Taiwanese Dollars.